Press Releases

Press Releases

Date Title
August 4, 2020
UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital
SAN FRANCISCO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it has entered into a $80 million debt facility with Hercules
July 31, 2020
UNITY Biotechnology, Inc. Reports Second Quarter 2020 Financial Results and Clinical Program Updates
SOUTH SAN FRANCISCO, Calif. , July 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter ended June
July 29, 2020
UPDATE – UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results
SAN FRANCISCO , July 29, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended
July 24, 2020
UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results
SAN FRANCISCO , July 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended
July 6, 2020
UNITY Biotechnology Announces CFO Transition
Lynne Sullivan appointed interim chief financial officer SAN FRANCISCO , July 06, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that
July 1, 2020
UNITY Biotechnology, Inc. Provides Updates on Lead Development Programs
– Topline 12-week results for Phase 2 study of UBX0101 in osteoarthritis expected in 3Q 2020 – – First-in-human study for UBX1325 in age-related eye disease expected to commence in 2H 2020 – SOUTH SAN FRANCISCO, Calif. , July 01, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc.
June 11, 2020
UNITY Biotechnology to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
SAN FRANCISCO , June 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the
May 7, 2020
UNITY Biotechnology, Inc. Reports First Quarter 2020 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the first quarter ended March
May 4, 2020
UNITY Biotechnology, Inc. to Announce First Quarter 2020 Financial Results
SAN FRANCISCO , May 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the first quarter ended
March 31, 2020
UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101
– Topline 12- and 24-week results expected in 2H 2020 – SAN FRANCISCO , March 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced updates
Displaying 1 - 10 of 16